FACULTY
Ryan Jacobs, MD
Clinical Assistant Professor of Medicine
UNC-Chapel Hill School of Medicine
Chapel Hill, NC
Director of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Levine Cancer Institute/Atrium Healthcare
Charlotte, NC
PROGRAM OVERVIEW
This enduring activity will cover the treatment and management of patients with chronic lymphocytic leukemia (CLL).
TARGET AUDIENCE
This activity is designed to meet the needs of US-based hematologists, medical oncologists, oncology nurses, and other healthcare providers involved in the treatment of patients with CLL.
LEARNING OBJECTIVES
Upon completion of the activity, attendees should be able to:
- Assess the treatment implications of common mutations and abnormalities for patients with previously untreated and relapsed/refractory (R/R) CLL;
- Describe current and novel therapeutic approaches for patients with previously untreated and R/R CLL;
- Develop treatment plans individualized for each patient with previously untreated or R/R CLL that integrate new agents and account for risks related to adverse events; and
- Discuss strategies that will improve communication, engagement, education, and decision making with patients with previously untreated and R/R CLL and their healthcare providers.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with CLL.
CNE Credits: 1.0 ANCC Contact Hour(s)
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Ryan Jacobs has served on the speakers’ bureau for AstraZeneca, Pharmacyclics, Janssen, Genentech, and AbbVie. He has received consultant fees from Pharmacyclics, Janssen, Genentech, and AbbVie.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete the online evaluation form.
You will receive your certificate after the enduring activity.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at; [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: September 13, 2019
EXPIRATION DATE: September 13, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.